Meridian Bioscience, Inc.
http://www.meridianbioscience.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Meridian Bioscience, Inc.
Korean Vs Global Biopharma M&A Trends: How Different Are They?
A number of recent significant transactions in the South Korean biopharma space indicate some emerging trends as the sector develops and expands internationally. Scrip takes a look at the over-arching themes in M&A activity over the past few years and how these may differ from those being observed globally.
Three Facing Fraud Charges In Magellan Lead Test Debacle
The now-Meridian subsidiary’s former CEO, COO and regulatory affairs director reportedly delayed telling the FDA and the public about incorrect results obtained from Magellan’s LeadCare line of blood tests.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Meridian Bioscience Acquired By SD Biosensor In $1.53Bn Cash Deal
Diagnostic kit maker Meridian Bioscience will be acquired by South Korean firms SD Biosensor and PE firm SJL Partners, accelerating entry into US market.
Company Information
- Industry
- Biotechnology
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Bioline
- Exalenz Bioscience Ltd.
- GenePOC Inc.
- Magellan Biosciences, Inc., Magellan Diagnostics
- Meridian Diagnostics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice